Andrew Tsourkas
Overview
Explore the profile of Andrew Tsourkas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
3418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Minutolo N, Sharma P, Poussin M, Shaw L, Brown D, Hollander E, et al.
J Am Chem Soc
. 2020 Mar;
142(14):6554-6568.
PMID: 32191035
Universal immune receptors represent a rapidly emerging form of adoptive T-cell therapy with the potential to overcome safety and antigen escape challenges faced by conventional chimeric antigen receptor (CAR) T-cell...
32.
Liu J, Lan Z, Ferrari C, Stein J, Higbee-Dempsey E, Yan L, et al.
ACS Nano
. 2019 Dec;
14(1):142-152.
PMID: 31854966
Drug delivery to solid tumors is hindered by hydrostatic and physical barriers that limit the penetration of nanocarriers into tumor tissue. When exploiting the enhanced permeability and retention (EPR) effect...
33.
Yan L, Luo L, Amirshaghaghi A, Miller J, Meng C, You T, et al.
Bioconjug Chem
. 2019 Oct;
30(11):2974-2981.
PMID: 31661959
Photodynamic therapy (PDT) has attracted extensive attention in recent years as a noninvasive and locally targeted cancer treatment approach. Nanoparticles have been used to improve the solubility and pharmacokinetics of...
34.
Wang H, Tsourkas A
Proc Natl Acad Sci U S A
. 2019 Oct;
116(44):22132-22139.
PMID: 31611380
Antibodies can be developed to directly inhibit almost any protein, but their inability to enter the cytosol limits inhibitory antibodies to membrane-associated or extracellular targets. Developing a cytosolic antibody delivery...
35.
Zappala F, Tsourkas A
Methods Mol Biol
. 2019 Jul;
2033:275-286.
PMID: 31332760
The high specificity and strong binding affinity of antibodies, most commonly immunoglobulin G (IgG), have led to their use in a wide range of research, diagnostic and therapeutic applications. Many...
36.
Bouche M, Puhringer M, Iturmendi A, Amirshaghaghi A, Tsourkas A, Teasdale I, et al.
ACS Appl Mater Interfaces
. 2019 Jul;
11(32):28648-28656.
PMID: 31321973
Overproduction of reactive oxygen species (ROS) is often related to inflammation or cancer and can cause tissue damage. Probes that have been previously reported to image ROS typically rely on...
37.
Liu J, Jang B, Issadore D, Tsourkas A
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2019 Jun;
11(6):e1571.
PMID: 31241251
Drug delivery strategies aim to maximize a drug's therapeutic index by increasing the concentration of drug at target sites while minimizing delivery to off-target tissues. Because biological tissues are minimally...
38.
Wang H, Tsourkas A
Methods Mol Biol
. 2019 Jun;
2012:15-28.
PMID: 31161501
S. aureus sortase A (SrtA), a calcium-dependent transpeptidase, is frequently employed to site-specifically label the C-terminus of recombinant proteins bearing an LPXTG SrtA recognition motif. Unfortunately, SrtA suffers from low...
39.
Wang H, Tsourkas A
Methods Mol Biol
. 2019 May;
2008:165-177.
PMID: 31124096
S. aureus sortase A (SrtA), a calcium-dependent bacterial transpeptidase, is commonly used to site-specifically label proteins containing a LPXTG SrtA recognition motif with a wide array of chemical moieties. A...
40.
Amirshaghaghi A, Yan L, Miller J, Daniel Y, Stein J, Busch T, et al.
Sci Rep
. 2019 Feb;
9(1):2613.
PMID: 30796251
Photodynamic therapy (PDT) is an approved modality for the treatment of various types of maligancies and diseased states. However, most of the available photosensitizers (PS) are highly hydrophobic, which limits...